Nebivolol (Bystolic®), a novel, highly cardioselective, third-generation β-blocker that recently received approval by the US FDA for the treatment of hypertension in the USA, is effective in ...
Purpose. The pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of nebivolol are reviewed. Summary. Nebivolol, a third-generation, highly β 1-specific β-blocker, is labeled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback